Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kempler, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Autonomic neuropathy: a marker of cardiovascular risk

Peter Kempler

Department of Medicine, Semmelweis University, 1083 Budapest, Korányi S.u. 2/a, Hungary, eva.kempet{at}ediport.hu

Cardiac autonomic neuropathy (CAN) represents a serious complication as it carries an approximately five-fold risk of mortality in patients with diabetes just as in those with chronic liver diseases. The high mortality rate may be related to silent myocardial infarction, cardiac arrhythmias, cardiovascular and cardiorespiratory instability and to other causes not yet explained. Resting tachycardia due to parasympathetic damage may represent one of the earliest signs. Typical findings referring to autonomic dysfunction may include exercise intolerance, orthostatic hypotension and cardiac dysfunction to rest or exercise. Severe autonomic neuropathy may be responsible for spontaneous respiratory arrest and unexplained sudden death. A relationship between the presence and/or severity of CAN and corrected QT interval prolongation is well documented. Better understanding of the prognostic importance of autonomic neuropathy followed the use of simple non-invasive cardiovascular reflex tests. These most commonly include heart rate variation in response to deep breathing, standing, the Valsalva maneouvre and blood pressure response to standing and sustained handgrip. Near normoglycaemia is now generally accepted as the primary approach to the prevention of diabetic neuropathy, but is not achievable in most patients. Our experience of the use of the antioxidant alpha-lipoic acid in the treatment of cardiac autonomic neuropathy is described.

Key Words: autonomic neuropathy • cardiovascular risk • QT interval • cardiovascular reflex tests • benfotiamin • alpha-lipoic acid.

References

  • Eichorst H. Beiträge zur Pathologie der Nerven und Muskeln. Archiv Pathol Anat Physiol Klin Med 1892;127:1-17.[CrossRef]
  • Wieling W., Smit AAJ, Karemaker JM Diabetic autonomic neuropathy: conventional cardiovascular laboratory testing and new developments. Neuroscience Research Communications 1997;21:67-74.[CrossRef][Web of Science]
  • Wheeler T., Watkins PJ Cardiac denervation in diabetes. BMJ 1973;4: 584-6.[Abstract/Free Full Text]
  • Ewing DJ, Campbell IW, Burt AA, Clarke BF Vascular reflexes in diabetic autonomic neuropathy. Lancet 1973;2:1354-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Greene DA, Stevens MJ Interaction of metabolic and vascular factors in the pathogenesis of diabetic neuropathy. In: Hotta N, Greene DA, Ward DJ, Sima AAF, Boulton AJM, (eds.). Diabetic Neuropathy: New Concepts and Insights. Amsterdam, The Netherlands: Elsevier Science B.V. 1995;37-41.
  • Ward JD Diabetic neuropathy. In: KGMM Alberti, RA DeFronzo, H Keen, P Zimmet (eds.). International Textbook of Diabetes Mellitus. Chichester: John Wiley and Sons Ltd. 1992;59:1385-414.
  • Tesfaye S., Harris N., Jakubowski JJ et al. Impaired blood flow and arteriovenous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993;36: 1266-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.[Abstract]
  • Boulton AJM (ed.). Diabetic Neuropathy. Carnforth, UK: Marius Press, 1997:41-61.
  • Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999;42:773-88.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kempler P., Tesfaye S., Chaturvedi N. et al. The EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002;19:900-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gottsäter A., Ahmed M., Fernlund P., Sundkvist G. Autonomic neuropathy in type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. Diabet Med 1999;16:49-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Szelag B., Wroblewski M., Castenfors J. et al. Obesity, microalbuminuria, hyperinsulinemia and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care 1999;22:1907-08.[Free Full Text]
  • Valensi P., Paries J., Lormeau B., Assad N., Attali JR Cardiac parasympathetic changes: a new component of the insulin resistance syndrome. Diabetes 1999;48(suppl 1):A149(abstract).
  • Ziegler D. Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment. Diabetes Metab Rev 1994;10:339-83.[Web of Science][Medline] [Order article via Infotrieve]
  • Hendrickse MT, Thuluvath PJ, Triger DR The natural history of autonomic neuropathy in chronic liver disease. Lancet 1992;339:1462-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Palatini P., Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997;15:13-17.
  • Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. Diabetologia 1997;40:476-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jermendy G., Tóth L., Vörös P., Koltay MZ, Pogátsa G. QT-interval in diabetic autonomic neuropathy. Diabet Med 1990;7:750.[Web of Science][Medline] [Order article via Infotrieve]
  • Kempler P., Váradi A., Szalay F., Tamás GY Autonomic neuropathy and corrected QT interval prolongation: there is a relationship. Diabetes Care 1994;17:454-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Kempler P., Váradi A., Szalay F. Autonomic neuropathy and prolongation of QT-interval in liver disease. Lancet 1992;340:318.[Medline] [Order article via Infotrieve]
  • Kempler P., Keresztes K., Hermányi ZS, Marton A. Studies must establish whether prolonged QTc interval in newly diagnosed type 1 diabetes is reversible. BMJ 1998;317:678-9.[Free Full Text]
  • Krahulec B., Strobová L., Balalovjech I. Hypertension is a prominent feature of diabetic autonomic neuropathy. a 10-year follow-up study. Diabetologia 1996;39(suppl 1):36A(abstract).
  • Spallone V., Maiello MR, Cicconetti E., Menzinger G. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non-insulin-dependent diabetes. Diab Res Clin Pract 1997;34:169-79.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Maser RE, Pfeifer MA, Dorman JS, Kuller RH, Becker DJ, Orchard TJ Diabetic autonomic neuropathy and cardiovascular risk. Arch Intern Med 1990;150:1218-22.[Abstract/Free Full Text]
  • Kempler P., Hermányi Zs, Keresztes K., Marton A. Klinische und prognostische Bedeutung der kardialen autonomen Neuropathie. In: Gries FA, Federlin K, (eds.). Benfotiamin in der Therapie von Polyneuropathien. Stuttgart- New York: Thieme Verlag, 1998:39-44.
  • Gambardella S., Frontoni S., Spallone V. et al. Increased left ventricular mass in normotensive diabetic patients with autonomic neuropathy. Am J Hypertens 1993;6:97-102.[Web of Science][Medline] [Order article via Infotrieve]
  • Jermendy GY, Ferenczy J., Hernandez E., Farkas K., Nádas J. Day-night blood pressure variation in normotensive and hypertensive NIDDM patients with asymptomatic autonomic neuropathy. Diabetes Res Clin Pract 1996;34:107-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jermendy GY Sympathovagal balance and cardiovascular diseases in diabetic patients with autonomic neuropathy. Diab Nutr Metab 1995;8: 123-4.
  • Vinik AI, Zola BE The effects of diabetic autonomic neuropathy on the cardiovascular system. In: Schwartz CJ, Born GVR, (eds.). New Horizons in Diabetes Mellitus and Cardiovascular Disease. London, UK: Current Science Ltd, 1995:159-71.
  • Beck MO, Silveiro SP, Friedman R., Clausell N., Gross JL Asymptomatic coronary artery disease is associated with cardiac autonomic neuropathy and diabetic nephropathy in type 2 diabetic patients. Diabetes Care 1999;22:1745-7.[Medline] [Order article via Infotrieve]
  • Airaksinen KEJ. Silent coronary artery disease in diabetes - a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001;44:259-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Valensi P., Sachs RN, Harfouche B. et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24:339-43.[Abstract/Free Full Text]
  • Kleiger RE, Miller JP, Bigger JT, Moss AJ and the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC Frequency domain measures of heart period variability to assess risk late after myocardial infarction. JACC 1993;21:729-36.[Abstract]
  • La Rovere MT, Bigger JT, Marcus FI, Mortara A., Schwartz PJ, for the ATRAMI Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lengyel CS, Török T., Várkonyi T., Kempler P., Rudas L. Baroreflex sensitivity and heart-rate variability in insulin-dependent diabetics with polyneuropathy. Lancet 1998;351:1436-7.[Medline] [Order article via Infotrieve]
  • Ewing DJ, Clarke BF Diagnosis and management of diabetic autonomic neuropathy. BMJ 1982;285:916-18.[Free Full Text]
  • American Diabetes Association, American Academy of Neurology: Consensus statement. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11:592-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Valensi P., Attali JR, Gagant S. and the French Group for Research and Study of Diabetes Neuropathy. Reproducibility of parameters for assessment of diabetic neuropathy. Diabet Med 1993;10:933-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Ewing DJ, Marty CN, Young RJ, Clarke BF The value of cardiovascular autonomic function tests: 10 years experiences in diabetes. Diabetes Care 1985;8:491-8.[Abstract]
  • Kempler P., Tesfaye S., Chaturvedi N. et al. The EURODIAB IDDM Complications Study Group. Blood pressure response to standing in the diagnosis of autonomic neuropathy: the EURODIAB IDDM Complications Study. Arch Physiol Biochem 2001;109:215-22.[CrossRef][Medline] [Order article via Infotrieve]
  • Whitsel EA, Boyko EJ, Siscovick DS Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes. Diabetes Care 2000;23:241-7.[Abstract]
  • Naas AAO, Davidson NC, Thompson C. et al. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent: cohort study. BMJ 1998;316:745-6.[Free Full Text]
  • Lengyel CS, Thury A., Várkonyi T. et al. Disturbances of heart rate variability and spatial and circadian QT intervals in diabetic patients with cardiac autonomic neuropathy. Hung Arch Int Med 1997;50:431-8.
  • Murata K., Sumida Y., Murashima S. et al. A novel method for the assessment of autonomic neuropathy in type 2 diabetic patients: a comparative evaluation of 123I-MIBG myocardial scintigraphy and power spectral analysis of heart rate variability. Diabetic Med 1996;13:266-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schnell O., Muhr D., Dresel S. et al. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients. Diabetologia 1996;39:970-5.[Medline] [Order article via Infotrieve]
  • Kempler P., Váradi A., Tamás GY Autonomic neuropathy in newly diagnosed diabetes mellitus. Diabetes Care 1993;16:848-9.[Web of Science][Medline] [Order article via Infotrieve]
  • The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial. Diabetologia 1998;41:416-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ziegler D., Weise F., Langen KJ et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I] metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998;41:443-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Watkins PJ Clinical observations and experiments in diabetic neuropathy. Diabetologia 1992;35:2-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kempler P (ed.). Neuropathies. Nerve Dysfunction of Diabetic and Other Origin. Budapest, Hungary: Springer Verlag, 1997.
  • Ziegler D., Mühlen H., Rathmann W., Gries FA Effects of one year's treatment with gamma-linolenic acid (EF4) on diabetic neuropathy. Diabetes 1993;42(suppl 1):99A(abstract).
  • Johansson BL, Fernquist-Forbes E., Odergren T., Remahl S., Wahren J. C-peptide improves automatic nerve function in IDDM patients. Diabetologia 1996;39:687-95.[Medline] [Order article via Infotrieve]
  • Booth AA, Khalifah RG, Hudson BG Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996;220:113-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bitsch R., Wolf M., Möller J., Heuzeroth L., Grüneklee D. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivate. Ann Nutr Metab 1991;35:292-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Stracke H., Lindemann A., Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996;104:311-16.[Web of Science][Medline] [Order article via Infotrieve]
  • Koltai MZ, Pósa I., Winkler G., Kocsis E., Pogátsa G. The preventive effect of benfotiamine on the development of cardiac autonomic neuropathy in diabetic dogs. Hung Arch Int Med 1997;50:443-8.
  • Nagamatsu M., Mickander KK, Schmelzer JD et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18: 1160-7.[Abstract]
  • Jacob S., Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ Improvement of insulin-stimulated glucose disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996;104:284-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Ziegler D., Hanefeld M., Ruhnau KJ et al. The ALADIN Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3 week multicenter randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ziegler D., Schatz H., Conrad F., Ulrich H., the DEKAN Study Group, Reichel G., Gries FA Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. Diabetes Care 1997; 20:369-73.[Abstract]
  • Ziegler D., Reljanovic M., Mehnert H., Gries FA Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107:421-30.[Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 2, 84-90 (2003)
DOI: 10.1177/14746514030030020201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kempler, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?